Clinical Trial: Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer

Brief Summary: Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Detailed Summary:

Patients will be recruited among patient refered to our department for a breast cancer and needing an axillary dissection. Enrolled patients will have an injection of Lanreotide or placebo the day before surgery when they arrive in their room. The quantity of lymph in axillary drain will by daily noted until day 4. The patient will be evaluated at D15, D30 and M6 for pain, lymphocele and adverse events.

Data will be compared in the 2 groups.

Sponsor: University Hospital, Limoges

Current Primary Outcome: Quantity of lymph collected by the drain [ Time Frame: D4 post operativly ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Prevention of lymphocele [ Time Frame: D15, D30 and M6 ]

Original Secondary Outcome: Same as current

Information By: University Hospital, Limoges

Dates:
Date Received: February 27, 2008
Date Started: March 2008
Date Completion:
Last Updated: January 13, 2012
Last Verified: January 2012